CI

At a glance

ClinicalIndex Comparison Record
N/ACompleted· 5,163 enrolled
Drug / intervention
Is it coronary artery embolismother
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT06845956
NCT06845956N/ACompleted

Prevalence, Clinical Features, and Prognosis of Coronary Artery Embolism With Concomitant Atrial Fibrillation

First Affiliated Hospital of Ningbo University·observational·Posted Feb 25, 2025·Updated Feb 25, 2025

In Brief

An observational study evaluating Is it coronary artery embolism for Coronary Artery Embolism and Acute Myocardial Infarction Type 2. Completed, enrolled 5,163 participants across 2 sites.

Detailed Summary

The goal of this observational study is to learn about the Prevalence, Clinical Features, and Prognosis of Coronary Artery Embolism With Concomitant Atrial Fibrillation. The main question it aims to answer is: What is the proportion of coronary artery embolism with concomitant atrial fibrillation among all myocardial infarctions and myocardial infarctions with concomitant atrial fibrillation? What are the clinical characteristics of coronary artery embolism with concomitant atrial fibrillation? What is the prognosis of coronary artery embolism with concomitant atrial fibrillation? All participants will receive routine diagnosis and treatment, and baseline demographic data, clinical examination laboratory results, and follow-up data will be collected for analysis.

Study Details

Study Typeobservational
Allocation--
Masking--
Primary Purpose--
CountriesChina
Collaborators--

Timeline

N/ACompletedFinished
20252026
First PostedFeb 25, 2025
Enrollment StartMay 1, 2024
Primary CompletionDec 31, 2024
TodayJul 2, 2026
Enrollment to primary: 8 monthsPosted 1.4 years ago

Interventions

Is it coronary artery embolismother

This observational study categorizes patients with acute myocardial infarction (AMI) into three distinct groups based on their clinical characteristics: 1. Group 1: Patients with atrial fibrillation (AF) and coronary artery embolism (CAE). 2. Group 2: Patients with AF but non-coronary artery embolism myocardial infarction (non-CAE MI). 3. Group 3: Patients without AF and non-coronary artery embolism myocardial infarction (non-CAE MI without AF). A key innovation of this study compared to previous research is its expanded eligibility criteria for AMI patients. Earlier studies typically focused exclusively on ST-segment elevation myocardial infarction (STEMI). In contrast, this investigation encompasses a broader spectrum of acute myocardial infarction, including both STEMI and non-ST-segment elevation myocardial infarction (NSTEMI). This comprehensive approach enhances the generalizability and applicability of the findings by capturing a wider range of clinical scenarios.